Biogen Inc. (BMV:BIIB)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of MXN 420.07 billion. The enterprise value is 468.88 billion.

Market Cap	420.07B
Enterprise Value	468.88B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.70M
Shares Outstanding	n/a
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	89.93%
Float	146.31M

Valuation Ratios

The trailing PE ratio is 14.24 and the forward PE ratio is 11.05.

PE Ratio	14.24
Forward PE	11.05
PS Ratio	2.28
PB Ratio	1.26
P/TBV Ratio	9.60
P/FCF Ratio	9.94
P/OCF Ratio	9.33
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.17, with an EV/FCF ratio of 11.09.

EV / Earnings	15.89
EV / Sales	2.51
EV / EBITDA	7.17
EV / EBIT	9.55
EV / FCF	11.09

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.36.

Current Ratio	2.72
Quick Ratio	1.77
Debt / Equity	0.36
Debt / EBITDA	1.87
Debt / FCF	2.86
Interest Coverage	10.18

Financial Efficiency

Return on equity (ROE) is 9.31% and return on invested capital (ROIC) is 6.92%.

Return on Equity (ROE)	9.31%
Return on Assets (ROA)	5.75%
Return on Invested Capital (ROIC)	6.92%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	24.28M
Profits Per Employee	3.88M
Employee Count	7,605
Asset Turnover	0.35
Inventory Turnover	1.01

Taxes

In the past 12 months, Biogen has paid 5.42 billion in taxes.

Income Tax	5.42B
Effective Tax Rate	15.52%

Stock Price Statistics

The stock price has decreased by -25.28% in the last 52 weeks. The beta is 0.13, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	-25.28%
50-Day Moving Average	2,713.56
200-Day Moving Average	3,925.56
Relative Strength Index (RSI)	56.49
Average Volume (20 Days)	291

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.21

Income Statement

In the last 12 months, Biogen had revenue of MXN 184.63 billion and earned 29.50 billion in profits. Earnings per share was 201.30.

Revenue	184.63B
Gross Profit	141.36B
Operating Income	48.53B
Pretax Income	34.92B
Net Income	29.50B
EBITDA	62.53B
EBIT	48.53B
Earnings Per Share (EPS)	201.30

Balance Sheet

The company has 72.64 billion in cash and 120.88 billion in debt, giving a net cash position of -48.23 billion.

Cash & Cash Equivalents	72.64B
Total Debt	120.88B
Net Cash	-48.23B
Net Cash Per Share	n/a
Equity (Book Value)	333.97B
Book Value Per Share	2,276.52
Working Capital	103.57B

Cash Flow

In the last 12 months, operating cash flow was 45.00 billion and capital expenditures -2.74 billion, giving a free cash flow of 42.27 billion.

Operating Cash Flow	45.00B
Capital Expenditures	-2.74B
Free Cash Flow	42.27B
FCF Per Share	n/a

Margins

Gross margin is 76.56%, with operating and profit margins of 26.28% and 15.98%.

Gross Margin	76.56%
Operating Margin	26.28%
Pretax Margin	18.92%
Profit Margin	15.98%
EBITDA Margin	33.87%
EBIT Margin	26.28%
FCF Margin	22.89%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	7.02%
FCF Yield	10.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3 and a Piotroski F-Score of 6.

Altman Z-Score	3
Piotroski F-Score	6